Do I need a prescription for Nicardipine 25mg/10ml solution for infusion ampoules?

Nicardipine 25mg/10ml solution for infusion ampoules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Nicardipine 25mg/10ml solution for infusion ampoules?

Nicardipine 25mg/10ml solution for infusion ampoules is the generic name. It is available under brand names including: Cardene I.V. 25mg/10ml solution for infusion ampoules. (Source: NHS dm+d — Actual Medicinal Products)

Nicardipine 25mg/10ml solution for infusion ampoules

Prescription only

Requires a prescription from a doctor or prescriber

Infusion

25mg/10ml

Other

Oral liquids

Antihypertensive

A potent calcium channel blockader with marked vasodilator action.

Active ingredients:

Nicardipine

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C08CA04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Check interactions for Nicardipine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Nicardipine

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Nicardipine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Nicardipine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Part of the Cardene brand family (generic: Nicardipine)

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Nicardipine on the MHRA register

Cardene I.V. 25mg/10ml solution for infusion ampoules

Imported (United States)

None

Imported

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Therapeutically similar medicines

10 similar

Amlodipine 2.5mg tablets

Tablet

2.5mg

Same therapeutic group

Lacidipine 6mg tablets

Tablet

6mg

Same therapeutic group

Amlodipine 5mg/5ml oral suspension sugar free

Oral suspension

5mg/5ml

Same therapeutic group

Nimodipine 60mg/5ml oral suspension

Oral suspension

60mg/5ml

Same therapeutic group

Felodipine 2.5mg/5ml oral suspension

Oral suspension

2.5mg/5ml

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

10646311000001108

dm+d ID

10646311000001108

VTM (Virtual Therapeutic Moiety)

776898007

VMP (Virtual Medicinal Product)

10646311000001108

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C08CA04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 18 · Randomised trials: 8 · 1980–2026

Sort

A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage

E. Clarke Haley, Neal F. Kassell, James C. Torner, et al.

Journal of neurosurgery, 1993

Randomised trial

Highly cited for its field

Cited by 359

Intracranial Aneurysm
Ischemic Attack, Transient
Infusions, Intravenous

A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study.

E. Haley, N. Kassell, J. Torner

Journal of neurosurgery, 1993

Randomised trial

Highly cited for its field

Cited by 168

Ischemic Attack, Transient
Infusions, Intravenous
Nicardipine

Systematic Review of Intrathecal Nicardipine for the Treatment of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage

Shaheryar Hafeez, Ramesh Grandhi

Neurocritical Care, 2019

Systematic review

Cited by 58

Blood Flow Velocity
Cerebrovascular Circulation
Injections, Intraventricular

A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.

Haley Ec, N. Kassell, J. Torner, et al.

Journal of neurosurgery, 1994

Randomised trial

Cited by 148

Abstract 275: Evaluating the Effectiveness of Nicardipine Prolonged Release Implants in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta‐Analysis

Khalil I, Hossain I

2024

Systematic review

A systematic review of nicardipine vs labetalol for the management of hypertensive crises

W. Frank Peacock, Daniel E. Hilleman, Phillip D. Levy, et al.

The American Journal of Emergency Medicine, 2011

Systematic review

Cited by 75

Acute Disease
Antihypertensive Agents
Hypertension

Nicardipine

Eugene M. Sorkin, Stephen P. Clissold

Drugs, 1987

Review

Highly cited for its field

Cited by 204

Angina Pectoris
Cardiovascular Diseases
Hypertension

Efficacy and safety of nicardipine prolonged-release implants in patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials.

Gonçalves OR, Nogueira LOS, de Maximiano MLB, et al.

2025

Meta-analysis

Subarachnoid Hemorrhage
Vasospasm, Intracranial
Nicardipine

Intrathecal nicardipine for cerebral vasospasm after non-traumatic subarachnoid hemorrhage: a meta-analysis.

Lima NL, da Silva Mezzari MH, Maggi BG, et al.

2025

Meta-analysis

Subarachnoid Hemorrhage
Vasospasm, Intracranial
Nicardipine

Evaluating the effectiveness of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage: a meta-analysis and meta-regression analysis.

Khalil I, Hossain I, Joy AD, et al.

2025

Meta-analysis

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

31 found

Half-life

8.6 hours

Mechanism

By deforming the channel, inhibiting ion-control gating mechanisms, and/or inter…

Food interactions

2 warnings

Human targets

19 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

35%

While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.…

Half-life

8.6 hours

8.6 hours

Protein binding

95%

>95%

Volume of distribution

8.3 L/kg

* 8.3 L/kg

Metabolism

Nicardipine HCl is metabolized extensively by the liver.

Elimination

Nicardipine has been shown to be rapidly and extensively metabolized by the liver.

Clearance

0.4 L/h

* 0.4 L/hr∙kg [Following infusion]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]

Properties:

solid

Avg. mass: 479.52 Da

View FDA drug label

DrugBank indication

Used for the management of patients with chronic stable angina and for the treatment of hypertension.

Also known as(237)

Nicardipine

Nicardipino

Nicardipinum

CACH2

CACN2

CACNL1A1

Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle

CCHL1A1

Molecular properties(19)

Drug interactions(2022)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Nicardipine is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Nicardipine is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Nicardipine may increase the hypotensive activities of Risperidone.

Check this interaction

Reserpine

Moderate

DB00206

Reserpine may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Simeprevir

Moderate

DB06290

Simeprevir may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Lenvatinib

Moderate

DB09078

Lenvatinib may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Nicardipine which could result in a higher serum level.

Check this interaction

Pralsetinib

Unknown severity

DB15822

The serum concentration of Pralsetinib can be increased when it is combined with Nicardipine.

Check this interaction

Ceritinib

Moderate

DB09063

Nicardipine may increase the bradycardic activities of Ceritinib.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Nicardipine.

Check this interaction

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Nicardipine.

Check this interaction

Amifostine

Moderate

DB01143

Nicardipine may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Nicardipine.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Obinutuzumab

Moderate

DB08935

Nicardipine may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Nicardipine.

Check this interaction

Rituximab

Moderate

DB00073

Nicardipine may increase the hypotensive activities of Rituximab.

Check this interaction

Desmopressin

Moderate

DB00035

Desmopressin may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Dopamine

Moderate

DB00988

Dopamine may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Epicaptopril

Moderate

DB02032

Epicaptopril may decrease the antihypertensive activities of Nicardipine.

Check this interaction

1-benzylimidazole

Moderate

DB04581

1-benzylimidazole may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Tyramine

Moderate

DB08841

Tyramine may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Moxisylyte

Moderate

DB09205

Moxisylyte may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Atipamezole

Moderate

DB11481

Atipamezole may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Idazoxan

Moderate

DB12551

Idazoxan may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Tramazoline

Moderate

DB13064

Tramazoline may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Fenozolone

Moderate

DB13341

Fenozolone may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Xenon

Moderate

DB13453

Xenon may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Buflomedil

Moderate

DB13510

Buflomedil may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Mefenorex

Moderate

DB13852

Mefenorex may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Quinoline Yellow WS

Moderate

DB14231

Quinoline Yellow WS may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Dutasteride

Moderate

DB01126

Dutasteride may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Naxitamab

Moderate

DB15965

Naxitamab may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Brexpiprazole

Moderate

DB09128

The metabolism of Brexpiprazole can be decreased when combined with Nicardipine.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Nicardipine.

Check this interaction

Everolimus

Moderate

DB01590

The metabolism of Everolimus can be decreased when combined with Nicardipine.

Check this interaction

Flibanserin

Moderate

DB04908

The metabolism of Flibanserin can be decreased when combined with Nicardipine.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Nicardipine.

Check this interaction

Ivabradine

Moderate

DB09083

The metabolism of Ivabradine can be decreased when combined with Nicardipine.

Check this interaction

Ivacaftor

Moderate

DB08820

The metabolism of Ivacaftor can be decreased when combined with Nicardipine.

Check this interaction

Lurasidone

Moderate

DB08815

The metabolism of Lurasidone can be decreased when combined with Nicardipine.

Check this interaction

Naloxegol

Moderate

DB09049

The metabolism of Naloxegol can be decreased when combined with Nicardipine.

Check this interaction

Olaparib

Moderate

DB09074

The metabolism of Olaparib can be decreased when combined with Nicardipine.

Check this interaction

Ranolazine

Moderate

DB00243

The metabolism of Ranolazine can be decreased when combined with Nicardipine.

Check this interaction

Showing 50 of 2022 interactions

Food & lifestyle interactions

Avoid Grapefruit

Avoid grapefruit products.

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

Oral LD₅₀ Rat = 184 mg/kg, Oral LD₅₀ Mouse = 322 mg/kg

How it works

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Pharmacodynamics

Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.

Half-life

8.6 hours

Protein binding

>95%

Volume of distribution

* 8.3 L/kg

Metabolism

Nicardipine HCl is metabolized extensively by the liver.

Route of elimination

Nicardipine has been shown to be rapidly and extensively metabolized by the liver.

Clearance

* 0.4 L/hr∙kg [Following infusion]

Drug targets(19)

Proteins and enzymes this drug interacts with in the body

Voltage-dependent L-type calcium channel subunit alpha-1C

BE0000430

CACNA1C

inhibitor

Specific functionalpha-actinin binding

Cellular location

Cell membrane

General function & pharmacology

Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents .
PMID:12181424 PMID:15454078 PMID:15863612 PMID:16299511 PMID:17224476 PMID:20953164 PMID:23677916 PMID:24728418 PMID:26253506 PMID:27218670 PMID:29078335 PMID:29742403 PMID:30023270 PMID:30172029 PMID:34163037 PMID:8099908

Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm .
PMID:15454078 PMID:15863612 PMID:17224476 PMID:24728418 PMID:26253506

Required for normal contraction of smooth muscle cells in blood vessels and in the intestine.

Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells .
PMID:28119464
Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable)

Voltage-dependent L-type calcium channel subunit beta-2

BE0002354

CACNB2

inhibitor

Specific functionactin filament binding

Cellular location

Cell membrane, sarcolemma

General function & pharmacology

Beta subunit of voltage-dependent calcium channels which contributes to the function of the calcium channel by increasing peak calcium current (By similarity). Plays a role in shifting voltage dependencies of activation and inactivation of the channel (By similarity). May modulate G protein inhibition (By similarity).

May contribute to beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force .
PMID:36424916
Involved in membrane targeting of the alpha-1 subunit CACNA1C PMID:17525370

Voltage-dependent calcium channel subunit alpha-2/delta-1

BE0000691

CACNA2D1

inhibitor

Specific functionmetal ion binding

Cellular location

Membrane

General function & pharmacology

The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel .
PMID:35293990
Plays an important role in excitation-contraction coupling (By similarity)

Voltage-dependent L-type calcium channel subunit alpha-1D

BE0002359

CACNA1D

inhibitor

Specific functionalpha-actinin binding

Cellular location

Membrane

General function & pharmacology

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.

They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines

Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A

BE0003565

PDE1A

inhibitor

Specific functioncalmodulin binding

General function & pharmacology

Calcium/calmodulin-dependent cyclic nucleotide phosphodiesterase with a dual specificity for the second messengers cGMP and cAMP, which are key regulators of many important physiological processes. Has a higher efficiency with cGMP compared to cAMP

Metabolizing enzymes(8)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

CYP2D6Cytochrome P450 2D6

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP2C8Cytochrome P450 2C8

substrate

inhibitor

CYP2B6Cytochrome P450 2B6

inducer

CYP2E1Cytochrome P450 2E1

substrate

CYP3A5Cytochrome P450 3A5

inhibitor

CYP2C9Cytochrome P450 2C9

inhibitor

Transporters(3)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Solute carrier organic anion transporter family member 1B1

BE0001004

SLCO1B1

inhibitor

Specific functionbile acid transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Mediates the Na(+)-independent uptake of organic anions .
PMID:10358072 PMID:15159445 PMID:17412826

Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) .
PMID:10358072 PMID:10601278 PMID:10873595 PMID:11159893 PMID:12196548 PMID:12568656 PMID:15159445 PMID:15970799 PMID:16627748 PMID:17412826 PMID:19129463 PMID:26979622

Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop .
PMID:22232210
Involved in the clearance of endogenous and exogenous substrates from the liver .
PMID:10358072 PMID:10601278
Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition .
PMID:26383540
May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs .
PMID:10601278 PMID:15159445 PMID:15970799

May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate .
PMID:23243220
May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver .
PMID:16624871 PMID:16627748
Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:19129463
Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions PMID:19129463

Bile salt export pump

BE0000703

ABCB11

substrate

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

ATC classification(1 code)

ATC C08CA04

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Nicardipine Hydrochloride(DBSALT000499)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Nicardipine

DB00622

CAS number

55985-32-5

UNII (FDA)

CZ5312222S

InChI Key (molecular fingerprint)

ZBBHBTPTTSWHBA-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1293

ChEBI

180905

PubChem Compound

4474

PubChem Substance

46504482

KEGG Compound

C07264

ChemSpider

4319

BindingDB

50101815

PharmGKB

PA450620

Therapeutic Targets Database

DAP000486

IUPHAR

2559

Guide to Pharmacology

2559

Wikipedia

Nicardipine

ChEMBL

CHEMBL1484

RxCUI

7396

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1399

GenAtlas

CACNA2D1

GeneCards

CACNA2D1

GenBank Gene Database

M76559

GenBank Protein Database

179762

UniProtKB

P54289

UniProt Accession

CA2D1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8774

GeneCards

PDE1A

GenBank Gene Database

U40370

GenBank Protein Database

1151109

Guide to Pharmacology

1294

UniProtKB

P54750

UniProt Accession

PDE1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8775

GenAtlas

PDE1B

GeneCards

PDE1B

GenBank Gene Database

U56976

Guide to Pharmacology

1295

UniProtKB

Q01064

UniProt Accession

PDE1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1405

GenAtlas

CACNG1

GeneCards

CACNG1

GenBank Gene Database

L07738

GenBank Protein Database

306473

UniProtKB

Q06432

UniProt Accession

CCG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1406

GeneCards

CACNG2

UniProtKB

Q9Y698

UniProt Accession

CCG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1407

GeneCards

CACNG3

UniProtKB

O60359

UniProt Accession

CCG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1408

GeneCards

CACNG4

UniProtKB

Q9UBN1

UniProt Accession

CCG4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1409

GeneCards

CACNG5

UniProtKB

Q9UF02

UniProt Accession

CCG5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13625

GeneCards

CACNG6

UniProtKB

Q9BXT2

UniProt Accession

CCG6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13626

GeneCards

CACNG7

UniProtKB

P62955

UniProt Accession

CCG7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13628

GeneCards

CACNG8

UniProtKB

Q8WXS5

UniProt Accession

CCG8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1399

GenAtlas

CACNA2D1

GeneCards

CACNA2D1

GenBank Gene Database

M76559

GenBank Protein Database

179762

UniProtKB

P54289

UniProt Accession

CA2D1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1400

GenAtlas

CACNA2D2

GeneCards

CACNA2D2

GenBank Gene Database

AJ251368

UniProtKB

Q9NY47

UniProt Accession

CA2D2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:15460

GeneCards

CACNA2D3

GenBank Gene Database

AJ272268

GenBank Protein Database

7105926

UniProtKB

Q8IZS8

UniProt Accession

CA2D3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20202

GeneCards

CACNA2D4

UniProtKB

Q7Z3S7

UniProt Accession

CA2D4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1393

GenAtlas

CACNA1F

GeneCards

CACNA1F

GenBank Gene Database

AJ006216

GenBank Protein Database

3183953

IUPHAR

531

Guide to Pharmacology

531

UniProtKB

O60840

UniProt Accession

CAC1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1403

GenAtlas

CACNB3

GeneCards

CACNB3

GenBank Gene Database

X76555

GenBank Protein Database

435135

UniProtKB

P54284

UniProt Accession

CACB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1404

GenAtlas

CACNB4

GeneCards

CACNB4

GenBank Gene Database

U95020

GenBank Protein Database

2058727

UniProtKB

O00305

UniProt Accession

CACB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1389

GenAtlas

CACNA1B

GeneCards

CACNA1B

GenBank Gene Database

M94172

GenBank Protein Database

179758

IUPHAR

533

Guide to Pharmacology

533

UniProtKB

Q00975

UniProt Accession

CAC1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1388

GenAtlas

CACNA1A

GeneCards

CACNA1A

GenBank Gene Database

AF004884

GenBank Protein Database

2213913

IUPHAR

532

UniProtKB

O00555

UniProt Accession

CAC1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1392

GeneCards

CACNA1E

Guide to Pharmacology

534

UniProtKB

Q15878

UniProt Accession

CAC1E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1394

GenAtlas

CACNA1G

GenBank Gene Database

AF134986

GenBank Protein Database

6625659

IUPHAR

535

Guide to Pharmacology

535

UniProtKB

O43497

UniProt Accession

CAC1G_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1395

GenAtlas

CACNA1H

GeneCards

CACNA1H

GenBank Gene Database

AF051946

GenBank Protein Database

14670397

IUPHAR

536

Guide to Pharmacology

536

UniProtKB

O95180

UniProt Accession

CAC1H_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1396

GenAtlas

CACNA1I

GeneCards

CACNA1I

GenBank Gene Database

AF129133

GenBank Protein Database

5565888

IUPHAR

537

Guide to Pharmacology

537

UniProtKB

Q9P0X4

UniProt Accession

CAC1I_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1394

GenAtlas

CACNA1G

GenBank Gene Database

AF134986

GenBank Protein Database

6625659

IUPHAR

535

Guide to Pharmacology

535

UniProtKB

O43497

UniProt Accession

CAC1G_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1395

GenAtlas

CACNA1H

GeneCards

CACNA1H

GenBank Gene Database

AF051946

GenBank Protein Database

14670397

IUPHAR

536

Guide to Pharmacology

536

UniProtKB

O95180

UniProt Accession

CAC1H_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1396

GenAtlas

CACNA1I

GeneCards

CACNA1I

GenBank Gene Database

AF129133

GenBank Protein Database

5565888

IUPHAR

537

Guide to Pharmacology

537

UniProtKB

Q9P0X4

UniProt Accession

CAC1I_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1442

GeneCards

CALM1

UniProtKB

P0DP23

UniProt Accession

CALM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1445

GeneCards

CALM2

UniProtKB

P0DP24

UniProt Accession

CALM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1449

GeneCards

CALM3

UniProtKB

P0DP25

UniProt Accession

CALM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10959

GenAtlas

SLCO1B1

GeneCards

SLCO1B1

GenBank Gene Database

AF060500

GenBank Protein Database

5051630

Guide to Pharmacology

1220

UniProtKB

Q9Y6L6

UniProt Accession

SO1B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(4 Mar 2026)

Structured knowledge from the free knowledge base

Q729213

Wikipedia article

chemical compound

Read on Wikipedia

WHO INN:nicardipine

International Nonproprietary Name

Research database identifiers

MeSH

D009529

ChEBI

CHEBI:180905

ATC classifications (Wikidata)

C08CA04

Linked open data from Wikidata (Q729213), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.

Source: Q729213CC0 1.0

Updated about 4 hours ago(5 Jul 2026)

Back to medicines

Nicardipine 25mg/10ml solution for infusion ampoules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
30

Chemical identifiers

Nicardipine

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Nicardipine 25mg/10ml solution for infusion ampoules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science30

Chemical identifiers

Nicardipine

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
30